Schall Law Firm, a national shareholder rights litigation firm,
announces that it is investigating claims on behalf of investors of
Akers Biosciences, Inc. (“Akers” or the “Company”) (NASDAQ: AKER)
for violations of §§10(b) and 20(a) of the Securities Exchange Act of
1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and
The investigation focuses on whether the Company issued false and/or
misleading statements and/or failed to disclose information pertinent to
investors. On May 21, 2018, Akers announced that it was unable to file
its Form 10-Q quarterly report with the SEC for the period ending March
31, 2018. The Company added that its internal review has expanded to
include the “characterization of certain revenue recognition items . . .
now includes certain transactions in previous quarters.” On May 22,
2018, shares of Akers fell more than 8% based on this news. On May 29,
2018, Akers announced that “Raymond F. Akers Jr., Ph.D. has resigned as
a director of the Company with immediate effect.” Akers shares fell 33%
the same day based on this announcement. On June 1, the Company released
a letter to the SEC from Dr. Raymond Akers stating that he “resigned
from the Board of Directors due to significant differences regarding the
policies and practices of the Board of Directors, accounting and
business practices of Management, and new Counsel.”
If you are a shareholder who suffered a loss, click
here to participate.
We also encourage you to contact Brian Schall, or Sherin Mahdavian, of
the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA
90067, at 424-303-1964, to discuss your rights free of charge. You can
also reach us through the firm’s website at www.schallfirm.com,
or by email at email@example.com.
The class in this case has not yet been certified, and until
certification occurs, you are not represented by an attorney. If you
choose to take no action, you can remain an absent class member.
The Schall Law Firm represents investors around the world and
specializes in securities class action lawsuits and shareholder rights
This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and rules of ethics.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180615005849/en/